Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma - Test2 - elhamkhani - TriplyDB

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

http://www.wikidata.org/entity/Q27021470

about

NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age Adaptation to antiangiogenic therapy in neurological tumors The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Antiangiogenic therapy for glioblastoma: current status and future prospects.Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform.Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model.Glioblastoma: Defining Tumor Niches.Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas.Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma.Identification of RSK and TTK as Modulators of Blood Vessel Morphogenesis Using an Embryonic Stem Cell-Based Vascular Differentiation Assay Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles.Lipid rafts: integrated platforms for vascular organization offering therapeutic opportunities.Genome-wide expression datasets of anti-VEGF and dexamethasone treatment of angiogenesis in the rat cornea.Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.Therapeutic application of anti-angiogenic nanomaterials in cancers.Glioblastoma invasion and cooption depend on IRE1α endoribonuclease activity.Receptor protein tyrosine phosphatase beta/zeta is a functional binding partner for vascular endothelial growth factor Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations.Regulation of Vegf signaling by natural and synthetic ligands.Radiologic Features and Expression of Vascular Endothelial Growth Factor Stratify Survival Outcomes in Patients with Glioblastoma.Disease progression patterns of bevacizumab responders with recurrent malignant gliomas.Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti-Vascular Endothelial Growth Factor Therapy-Induced Glioma Dissemination.Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration.Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma.Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties.VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance

P2860

Q26830388-0B13F2B6-F8E5-4FD2-AFA6-8678B58F241D Q28082908-F7C4E3FB-677A-4897-BE97-E60C14B8F577 Q34293163-A37924B7-C7E1-4F11-B19A-AAF9E8CBDCCF Q34523319-86793539-EECE-4962-BC2F-AB894EF08823 Q34807753-B545082E-5E44-4D17-8050-B347D4E206DA Q35133246-91779303-BB0C-4F15-8DA4-F55B5A8D41F2 Q35627827-614D2419-34B1-4A22-B300-6CBC7DBEA2E8 Q36228258-D9F71E79-3FAD-4E4A-88C5-B249A74450AA Q36484434-812FC48F-07CD-4ED4-B4EB-BA86EE77202F Q36796616-E9CD0D9E-7EEC-4629-A2DD-2ADAEC5EAB8F Q37085978-ED8A7711-01EB-4E9E-86F8-B3DA223F1A74 Q37317180-A56AF6E7-0770-44A3-B7EB-9D856E09671D Q37338152-073A795A-C1F1-4236-94DA-E4FE99E58A38 Q37389371-7333FE5C-AAF2-4624-8ACC-21A9F2676CF8 Q38304820-9BD50B3A-EEFB-42C0-B8CB-73FFE6538772 Q38623872-C44324F0-3401-490D-BCEE-784DF4F2B492 Q38773966-E605A470-3C6F-42F9-A53E-75C822717619 Q38805034-C797DA28-1747-40B2-9132-76ADB3B09988 Q38839149-A7C12E31-7ED4-419E-9199-6C21C82E4B74 Q38913862-524CDF1E-7F4B-413F-811A-40FBE9F633E3 Q38987239-FE06116C-013E-48BD-B470-F244B57BFCAB Q39022941-2F9614A4-D99E-4A89-8AA7-818AAD36AEEF Q39173162-8207F4EE-9752-4C9F-B4D9-8DEC83BDCA54 Q39232954-C18E6BC5-6FCA-4424-B92A-A2773CBC1CFB Q39456719-7F14525D-C7B5-4D4F-A787-DE3091E105F4 Q40301113-09FACF60-82D5-4945-99D7-3A2D10D87AA1 Q41616011-87DB6620-9C63-41B3-A72B-2809527819CC Q42284739-90E2C57D-8AF1-4B39-B106-3420A818F42E Q45070195-6B466F2E-F496-46F6-B79B-985D0F92764E Q47339574-521F56D4-0B7F-4A20-9F10-3188541B8C17 Q48184079-2133C10B-8386-44F4-9B3C-1F93F87BD231 Q48245198-063CC20A-20AF-49D9-BE49-0F4E20F02366 Q49887919-D21946B9-6EC6-43AE-9233-37669B4D4BE0 Q55064617-B658A927-B1BF-4C36-A192-8177F091D565 Q55289375-DEBF8330-8E1D-41EF-8D3E-73A27837FEF4 Q55312333-FB5FDF0C-0D25-4EC3-AE2C-AD070A1EDED8 Q55461236-5E52D136-1151-4D1B-8805-4A05C3E911D0 Q57291646-FA5FB3E1-D7C3-4C91-BA2E-344CE138F437

P2860

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

http://www.wikidata.org/entity/Q27021470

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

@ast

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

@en

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

@nl

type

label

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

@ast

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

@en

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

@nl

prefLabel

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

@ast

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

@en

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

@nl

P1433

Q27021470-FF967157-EE94-4AC9-B806-C8730DFF53C7

P1476

Q27021470-457AE32E-19B9-4E3C-B4AF-3224A1A23680

P2093

Q27021470-6E73EDAA-54D4-4FE4-8408-E7110EAAAB53

Q27021470-A6D467E9-67C5-414D-90BA-56DCFDDF7F42

P2860

Q27021470-01A52FDF-69C0-4A79-AE6C-D3EB3FC7360F

Q27021470-02E367C2-D211-4222-8E7C-8A7F99C4E0A5

Q27021470-04522D51-60C7-4061-8290-AE693183ADC5

Q27021470-0614F756-4D38-4AFF-82B0-015808A2259C

Q27021470-0683FC63-F8D1-4FDF-966B-1FDDBA52BCEA

Q27021470-07046815-6D18-4017-9B90-7158FC6EFB12

Q27021470-07A75FE9-EB6F-49DA-8DE9-1C350E0C5925

Q27021470-098D62C5-F415-4058-9B62-626FA7D0D734

Q27021470-0DED0FDB-8383-4E5B-A624-196172D74243

Q27021470-124105B5-4376-41F2-A9C6-BD64341AFA6B

P304

Q27021470-7DF94AF2-5F04-4044-8ECC-486AC8FE237C

P31

Q27021470-E11159FC-2B60-49BA-B7A7-92894B0FC63E

P3181

Q27021470-A9241937-4311-4707-B6D7-5903FB47F2F7

P356

Q27021470-129E0695-9DC7-4F58-9911-68C191B69883

P407

Q27021470-445C65E0-475B-43A6-B8EF-A686B5A45301

P433

Q27021470-0B75B5CB-2947-46FD-85AE-E66AC98603B7

P478

Q27021470-9FDE712E-575B-4416-813C-F4426A4F3219

P577

Q27021470-77F64F8F-E7A9-48A7-B518-DDFE9D396C6B

P698

Q27021470-D1D0594A-D8DE-49AB-B3DB-41B09234F981

P932

Q27021470-57427468-27B7-40B3-82E1-6DA2E72EE4DE

P3181

P356

P1433

P1476

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

@en

P2093

Gabriele Bergers

http://www.w3.org/2001/XMLSchema#string

Kan V Lu

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

The epithelial-mesenchymal transition generates cells with properties of stem cells

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

P304

49-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2042986

http://www.w3.org/2001/XMLSchema#string

P356

10.2217/CNS.12.36

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23750318

http://www.w3.org/2001/XMLSchema#string

P932

3673744

http://www.w3.org/2001/XMLSchema#string